13F HOLDINGS REPORT
Pfizer Inc
Quarter ended Q3 2025 · Filed November 13, 2025 · Accession 0000078003-25-000161
Total Value
$437.5M
Positions
24
Other Managers
0
Confidential Omitted
No
Holdings (24)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | BIONTECH SE | BNTX | 1,658,361 | $163.5M | 37.39% |
| 2 | ORIC PHARMACEUTICALS INC | ORIC | 5,376,344 | $64.5M | 14.75% |
| 3 | TOURMALINE BIO INC | 89157D105 | 1,272,214 | $60.8M | 13.91% |
| 4 | ARVINAS INC | ARVN | 3,457,815 | $29.5M | 6.73% |
| 5 | ALLOGENE THERAPEUTICS INC | ALLO | 22,032,040 | $27.3M | 6.25% |
| 6 | CELCUITY INC | CELC | 349,406 | $17.3M | 3.95% |
| 7 | WAVE LIFE SCIENCES LTD | WVE | 1,875,000 | $13.7M | 3.14% |
| 8 | PYXIS ONCOLOGY INC | PYXS | 5,952,263 | $13.2M | 3.02% |
| 9 | ZURA BIO LTD | ZURA | 2,970,022 | $12.9M | 2.94% |
| 10 | CARIBOU BIOSCIENCES INC | CRBU | 4,690,431 | $10.9M | 2.50% |
| 11 | BIOHAVEN LTD | BHVN | 505,645 | $7.6M | 1.73% |
| 12 | CARDIFF ONCOLOGY INC | CRDF | 2,411,575 | $5.0M | 1.14% |
| 13 | SPERO THERAPEUTICS INC | SPRO | 2,362,348 | $4.4M | 1.02% |
| 14 | PYXIS ONCOLOGY INC | PYXS | 1,080,507 | $2.4M | 0.55% |
| 15 | ZENTALIS PHARMACEUTICALS INC | ZNTL | 953,834 | $1.4M | 0.33% |
| 16 | AN2 THERAPEUTICS INC | ANTX | 715,295 | $908,425 | 0.21% |
| 17 | NEXTCURE INC | NXTC | 131,109 | $768,299 | 0.18% |
| 18 | Q32 BIO INC | QTTB | 277,777 | $549,998 | 0.13% |
| 19 | ESSA PHARMA INC | 29668H708 | 1,675,000 | $319,925 | 0.07% |
| 20 | BOLT BIOTHERAPEUTICS INC | BOLT | 31,305 | $166,543 | 0.04% |
| 21 | NEXTCURE INC | NXTC | 26,537 | $155,507 | 0.04% |
| 22 | GINKGO BIOWORKS HOLDINGS INC | DNABW | 2,681 | $39,089 | 0.01% |
| 23 | SENSEONICS HLDGS INC | SENS | 43,426 | $18,934 | 0.00% |
| 24 | GINKGO BIOWORKS HOLDINGS INC | DNABW | 247 | $3,601 | 0.00% |